Elan media headlines

Zacks.com - May 18, 2012 Alkermes (ALKS - Analyst Report) reported break-even earnings (including depreciation and stock-based compensation expenses) in the fourth quarter of fiscal 2012 (ended March 31, 2012).

ELAN CORPORATION, PLC : New Analysis of Risk Stratification for TYSABRI ... 4-traders - May 17, 2012 Biogen Idec (NASDAQ: BIIB) and Elan Corporation, plc (NYSE: ELN) today announced that the New England Journal of Medicine published research from the companies' global risk management program that updates the risk of TYSABRI ? (natalizumab)-associated ...

By Brian Orelli, The Motley Fool Gilenya was supposed to be the multiple sclerosis front runner, taking market share from treatments that have to be injected or infused because it's taken orally.

By Sean Williams , The Motley Fool Shares of Biogen Idec (NAS: BIIB) hit a 52-week high today. Let's take a look at how the company got there and whether clear skies are still in the forecast.

Elan Corp. (NYSE: ELN)'s stock had its ?buy? rating reiterated by equities research analysts at Jefferies Group (NYSE: JEF) in a research note issued to investors on Tuesday. Elan Corp (ELN) Up on Positive FDA Alzheimer's Disease Comments - StreetInsider.com (subscription)

Despite a lackluster broader market, shares of Elan Corp (NYSE: ELN) are 5 percent higher Tuesday. The upside could have something to do with comments from the FDA that is willing to consider an Alzheimer's Disease drug with a single outcome.

By Naomi Kresge on May 14, 2012 Roche Holding AG (ROG) is focusing part of its pipeline on the riskiest area of drug development: the human brain.

By Nathan Sadeghi-Nejad 05/14/12 - 07:00 AM EDT NEW YORK (TheStreet) -- I've been a professional investor for 15 years, and over that time I've listened to generalist investors gripe about the health care sector with mind-numbing cyclicality.

Barclays on Healthcare: Top Takeaways from our Second Annual Therapeutics ... StreetInsider.com (subscription) - May 11, 2012 Alzheimer's Disease - Disease modifying agents that produce modest disease progression delay could still be approved and widely used.

Reuters Key Development - May 8, 2012

PDL BioPharma Inc. (PDLI - Snapshot Report) posted first quarter earnings of 30 cents per share, above the year-ago figure of 25 cents and the Zacks Consensus Estimate of 26 cents.

PetMed Express (NASDAQ:PETS) Disappoints Investors with Results- PETS, VRX ... eStocksDaily - 17 hours ago Shares of pet pharmacy firm Petmed Express Inc (NASDAQ:PETS) plummeted 19% on Monday following the firm posted in its Q4 earnings how much and advertising blitz had reduced into profit.

Benzinga - May 7, 2012 By Monica Gerson Below are the top drug delivery stocks on the NYSE and the NASDAQ in terms of operating margin. The trailing-twelve-month operating margin at Valeant Pharmaceuticals International Inc (NYSE: VRX) is 24.98%.

DailyFinance - May 4, 2012 By Brian Orelli, The Motley Fool Multiple sclerosis drug Tysabri is arguably the most important drug to both Biogen Idec (NAS: BIIB) and Elan (NYS: ELN) .

NASDAQ - May 4, 2012 Acorda Therapeutics Inc. ( ACOR ) reported first quarter earnings (including share-based compensation charges) of 26 cents per share, compared to a loss of 2 cents in the year-ago period.